Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06390592
Other study ID # PD-SSH-01-INT
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date December 2025

Study information

Verified date April 2024
Source Fresenius Medical Care Deutschland GmbH
Contact Manuela Stauss-Grabo, Dr.
Phone +4961726085248
Email Manuela.Stauss-Grabo1@freseniusmedicalcare.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Analysis and comparison of treatments with and without the FlexPoint technology (flexible volume and dwell time management) of the PD cycler sleep•safe harmony


Description:

The primary objective of this study are: - to investigate and compare the clinical performance of standard (default) FlexPoint settings to minimum FlexPoint settings and to the maximum value for permitted peritoneal residual volume of FlexPoint settings of the PD cycler sleep•safe harmony in the treatment of PD patients. - to assess whether usage of the settings of the therapy option FlexPoint (flexible volume and dwell time management) of the PD cycler sleep•safe harmony that deviate from the system default and from former sleep•safe settings, influences the efficacy of APD treatments as well as the hydration status (by using BCM) of PD patients. The secondary objectives of this study are: - Patients´ Quality of Life (QoL) - Number of alarms - To investigate the effects on solute removal - To investigate the tolerability of the FlexPoint therapy options - Adverse events / SAE


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 24
Est. completion date December 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed consent signed and dated by study patient and investigator/ authorised physician - Minimum age of 18 years - CKD patients with indication for renal replacement therapy - Patients being treated with APD for at least 3 months - Patients using the sleep•safe harmony PD cycler (version 3.1) - Fluid status regularly monitored with Body Composition Monitor (BCM) - Proper functioning catheter - Intraperitoneal Pressure (IPP) = 18 cm H2O - Ability to understand the nature and requirements of the study Exclusion Criteria: - Any conditions which could interference with the patient's ability to comply with the study - Previous participation in the same study - Patients who have any condition prohibiting the use of BCM, like patients with major amputations (e.g. lower leg) - Patients receiving polyglucose containing PD solution - Respiratory or abdominal wall disease deemed to contraindicate intraperitoneal fill volume (FV) manipulation - Patients who suffer from peritonitis/exit site infection during the last 4 weeks - Women of childbearing age without effective means of contraception, pregnancy (pregnancy test will be conducted at start and end of study) or lactation period - Life expectancy <3 months - Participation in an interventional clinical study during the preceding 90 days

Study Design


Intervention

Device:
PD cycler
Patients are treated continuously during Peritoneal dialysis with the PD cycler sleep•safe harmony with different FlexPoint settings. According to their randomization the patients are treated with Treatment A, B or C in a different order: standard (default) FlexPoint settings (Treatment A) minimum value FlexPoint settings (Treatment B) maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Fresenius Medical Care Deutschland GmbH Alcedis GmbH

Outcome

Type Measure Description Time frame Safety issue
Primary Total Kt/V urea Measurement of solute removal during peritoneal dialysis focuses on urea every 2 weeks, during the 6 weeks treatment
Secondary Mean daily ultrafiltration (UF) Daily ultrafiltration reached by the patient during peritoneal dialysis every day, during the 6 weeks treatment
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4